Global Neurological Biomarkers Market, By Product Type (Genomics Biomarker, Proteomics Biomarker, Imaging Biomarker, Metabolomics Biomarker, Others), Indication (Spinal Muscular Atrophy, Parkinson’s Disease, Schizophrenia, Huntington’s Disease, Alzheimer’s Disease, Depression, Multiple Sclerosis), Imaging Techniques (Transcranial Magnetic Stimulation, Diffusion Tensor Imaging, Conventional Structural MRI, Functional Magnetic Resonance Imaging, Positron Emission Tomography), Services (Sample Preparation, Assay Development, Biomarker Validation and Testing), End- User (Clinical Diagnostics, Pharmaceutical And Biotechnology Companies, Research Organizations), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
The neurological biomarkers market is expected to witness market growth at a rate of 12.6% in the forecast period of 2021 to 2028. Data Bridge Market Research report on neurological biomarkers market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rapid advancements in the healthcare sector globally is escalating the growth of neurological biomarkers market.
Neurological biomarkers refer to the biomarkers that are regarded as criteria for assessing and calculating a method or symptom for acquiring a pharmacological response to a specific treatment. They are widely utilized for identifying various diseases such as autism, Parkinson disease and depression, among others. Imaging biomarker, genomics biomarker, proteomics biomarker and metabolomics biomarker are some of the common types of neurological biomarkers.
The increase in prevalence of neurological diseases across the globe acts as one of the major factors driving the growth of neurological biomarkers market. The rise in the use of neurological biomarkers for indicating the normal biological and pathogenic process to a therapeutic intervention, and increase in biobanks for addressing unmet needs in oncology, neuroscience, and cardiovascular disease accelerate the market growth. The increase in occurrence of neurological disorders, such as motor neuron disease (MND), Parkinson’s disease (PD), stroke, Alzheimer’s disease (AD), and Huntington’s disease (HD), and use of these biomarkers to measure the efficacy of new drugs and therapeutic strategies further influence the market. Additionally, neuro-disorders affecting the brain, spine, or nerves, proactive government initiatives, surge in healthcare expenditure and rise in telehealth positively affect the neurological biomarkers market. Furthermore, increase in personalized medicine and introduction of newer neurological biomarkers extend profitable opportunity to the market players in the forecast period of 2021 to 2028.
On the other hand, the absence of pre-analytical tests and legal issues with early diagnosis of Alzheimer's and Parkinson's diseases are expected to obstruct the market growth. Strict government regulation is projected to challenge the neurological biomarkers market in the forecast period of 2021-2028.
This neurological biomarkers market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on neurological biomarkers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Neurological Biomarkers Market Scope and Market Size
The neurological biomarkers market is segmented on the basis of product type, indication, imaging techniques, services and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the neurological biomarkers market is segmented into genomics biomarker, proteomics biomarker, imaging biomarker, metabolomics biomarker and others.
- On the basis of indication, the neurological biomarkers market is segmented into spinal muscular atrophy, parkinson’s disease, schizophrenia, huntington’s disease, alzheimer’s disease, depression, and multiple sclerosis.
- On the basis of imaging techniques, the neurological biomarkers market is segmented into transcranial magnetic stimulation, diffusion tensor imaging, conventional structural mri, functional magnetic resonance imaging, and positron emission tomography.
- On the basis of services, the neurological biomarkers market is segmented into sample preparation, assay development, and biomarker validation and testing.
- On the basis of end-user, the neurological biomarkers market is segmented into clinical diagnostics, pharmaceutical and biotechnology companies and research organizations.
Neurological Biomarkers Market Country Level Analysis
The neurological biomarkers market is analyzed and market size insights and trends are provided by country, product type, indication, imaging techniques, services and end user as referenced above.
The countries covered in the neurological biomarkers market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the neurological biomarkers market because of the increase in healthcare expenditure, and strong commercial performances of neurological diagnostics in the U.S. Asia-Pacific is expected to witness significant growth during the forecast period of 2021 to 2028 due to the improvement in healthcare infrastructure and increase in disposable income in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare infrastructure growth installed base and new technology penetration
The neurological biomarkers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neurological biomarkers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neurological biomarkers market. The data is available for historic period 2010-2019.
Competitive Landscape and Neurological Biomarkers Market Share Analysis
The neurological biomarkers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to neurological biomarkers market.
The major players covered in the neurological biomarkers market report are Athena Diagnostics, Inc., Quanterix, Immunarray Pvt. Ltd., QIAGEN, Bio-Rad Laboratories, Inc., BANYAN BIOMARKERS, INC, Merck KGaA,, F. Hoffmann-La Roche Ltd, Janssen Global Services, LLC,, Charles River, Advanced Brain Monitoring, Inc., Neurosteer, Quanterix, Myriad RBM, Abbott, and Thermo Fisher Scientific Inc, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Neurological Biomarkers Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.